Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. The company's work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.